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Background: ADAM8 (a disintegrin and a metalloprotease 8) has been linked to asthma and
eosinophilic pneumonia (EP). ADAM8 cleaves a variety of substrates and is a sheddase for
CD23, the low affinity IgE receptor. The concentration of soluble ADAM8 (sADAM8) is increased
in bronchoalveolar lavage fluid (BALF) from patients with smoking-induced acute eosinophilic
pneumonia (AEP) and chronic eosinophilic pneumonia (CEP), but not drug-induced EP (Drug-
EP). In AEP, the BALF sADAM8 concentration significantly correlates with the soluble CD23
concentration (sCD23).
Methods: To evaluate the involvement of ADAM8 in the pathogenesis of eosinophilic pneu-
monia, we measured the concentrations of sADAM8 and its substrate, soluble CD23 (sCD23),
in serum from patients with AEP, CEP, and Drug-EP. We also measured the change in the
sADAM8 concentration after a provocation test.
Results: In contrast to the BALF findings, serum sADAM8 concentrations were increased in
Drug-EP (mean SEM; 639.6 49.15) and serum ADAM8 levels correlated positively with the
serum sCD23 levels in patients with Drug-EP (PZ 0.0080, R2Z 0.8465). Serum sADAM8 concen-
trations were also increased in AEP (409  76.91) and CEP (644.7  87.03). Serum ADAM8
concentrations were also elevated after the provocation test.espiratory Disease, Osaka Minami Medical Center, Kidohigashimachi 2-1, Kawachinagano city, Osaka
04.
ita-u.ac.jp, matsuno@ommc-hp.jp (O. Matsuno).
9 Elsevier Ltd. All rights reserved.
Soluble ADAM8 in eosinophilic pneumonia 35Conclusion: Serum ADAM8 concentrations were elevated in Drug-EP, although the sADAM8
concentrations were not increased in the BALF in Drug-EP. Thus, the pathogenesis of AEP
and Drug-EP may be distinct with regard to allergen exposure; AEP may be caused by the inha-
lation of antigens, whereas Drug-EP may be caused by bloodstream antigens. These findings
indicate that ADAM8 levels reflect the route of eosinophilic inflammation in EP.
ª 2009 Elsevier Ltd. All rights reserved.Introduction
Eosinophils infiltrate the lung tissue, thereby impairing gas
exchange and inducing symptoms, such as dyspnea, fever,
and cough. This process may be secondary to several
factors, including exposure to drugs or parasite migration
and fungus, or it may be idiopathic. Eosinophilic pneumonia
(EP) is defined as the pulmonary infiltration of eosinophils
independent of peripheral blood eosinophilia. This pulmo-
nary disorder includes clinically different types of EP, such
as acute idiopathic eosinophilic pneumonia (AEP), chronic
eosinophilic pneumonia (CEP), and drug-induced eosino-
philic pneumonia (Drug-EP). Although these different forms
of EP have been clinically characterized,1e4 the pathogen-
esis of these different forms is not known.
ADAM (a disintegrin and a metalloprotease) family
members are implicated in the proteolytic processing of
membrane-bound precursors, and modulate cell-cell and
cell-matrix interactions. ADAM8 has metalloprotease
activity in vitro and catalyzes CD23, the low affinity IgE
receptor.5e7 CD23 has an important role in the modulation
of allergic pulmonary inflammation, likely mediated by
negative and positive signaling.8e12
ADAM8 is specifically induced in experimental asthma
and is highly expressed in human eosinophils.6,13 We
previously reported that soluble ADAM8 (sADAM8) signifi-
cantly inhibits experimental asthma.14 We also demon-
strated that sADAM8 levels are increased in bronchoalveolar
lavage fluid (BALF) samples from patients with cigarette
smoking-induced AEP and CEP, but for reasons that are not
clear, ADAM8 is not increased in BALF samples from patients
with Drug-EP.15 In addition, ADAM8 levels correlate posi-
tively with soluble CD23 (sCD23) levels in BALF from
patients with AEP.15
In the present study, we aimed to extend our earlier
study by measuring serum sADAM8 and sCD23 levels in
patients with EP. The findings reported in the present study
are the first to demonstrate that serum sADAM8 concen-
trations are increased in EP.
Method
Patients
We retrospectively analyzed 22 patients with EP (6 patients
with smoking-induced AEP, 8 patientswith CEP, and 8 patients
with Drug-EP) who were diagnosed at the Oita University
Faculty of Medicine Hospital and related hospitals from 1999
to 2006. Characteristics of the patients with EP are summa-
rized in the Table 1. Pulmonary eosinophilia was detected by
bronchoalveolar lavage and transbronchial lung biopsyspecimens. AEP was diagnosed according to the criteria
described by Allen.16 Most patients with AEP showed spon-
taneous improvement, although two patients required corti-
costeroid therapy for a few days. One of the six patients with
AEP had a history of pediatric asthma. In this study, idiopathic
AEP was not included. The diagnosis of CEP was made
according to the criteria described by Carrington et al.17 All
patients were treated with corticosteroids. The patients with
Drug-EP satisfied the following diagnostic criteria: fever or
some respiratory symptoms, diffuse pulmonary infiltrates on
chest X-ray films, increased percentage of eosinophils in
BALF, prompt improvement after cessation of the causative
drug, absence of other possible causes, or recurrence of the
symptoms with drug challenge. We also studied a control
group of 50 patients with non-eosinophilic lung disease; 10
patients with idiopathic pulmonary fibrosis [IPF], 10 patients
with sarcoidosis; and 30 healthy volunteers [HV]. Patients
with usual interstitial pneumonia associated with collagen
vascular diseases were excluded. In all 10 IPF cases, the
diagnosis was pathologically confirmed as usual interstitial
pneumonia. Sarcoidosis was diagnosed on the basis of typical
clinical features and the presence of epithelioid cell granu-
lomas in biopsy specimens from the lung, skin, or lymph
nodes. All tests were performed in the context of routine
medicalcare. None of the patients was treated with
glucocorticoids before the serum collection was completed.
The healthy volunteers provided informed consent.
Provocation test
According to Yasui’s method,18,19 provocation tests were
performed using the same drug and route of administration
as in the initial case. Drug provocation tests were performed
with careful observation and under informed consent. Thes
tests were started by administering the smallest dosage of
the suspected causal drug that could achieve a response,
and increasing the dose step-by-step at daily intervals until
reaching a normal daily dose or until symptoms occurred
(e.g., 10% of a single dose of medicine, then a single dose of
medicine, up to a normal daily dose for 3 days). If the same
adverse reaction occurred, drug administration was stopped
and the provocation test was considered positive, and the
next drug was then started. The drug provocation test was
judged positive according to Yasui’s criteria,18 modified
especially for EP.19,20 The current diagnostic criteria for
drug-induced pneumonia are two or more of the following
(including (1) or (2) and either (3), (4), or (5)); (1) 1 C
increase in body temperature, (2) skin rash, (3) increase in
the alveolar-arterial difference in oxygen tension (A-aDO2)
of more than10 mmHg, (4) more than 20% increase in the
number of WBC or eosinophilia in the peripheral blood, (5)
positive conversion of C reactive protein.
Table 1 Subject characteristics.
AEP CEP Drug-EP HV
Sex (M/F) (4/2) (3/5) (5/3) (12/18)
Age 21.17 3.08 67.88 4.12 64.25 6.64 39.90 2.22
ADAM8 (pg/ml) 409 76.91 644.7 87.03 639.6 49.15 239.8 23.87
CD23 (U/ml) 27.63 9.12 46.56 9.84 92.75 34.4 16.14 5.5
BAL
Total cells (105/ml) 8.25 2.20 13.64 3.83 5.66 2.15 N.D
Eo (%) 54.55 7.25 53.39 8.44 34.10 2.63 N.D
Lym (%) 17.68 4.73 11.28 6.16 15.06 3.59 N.D
Neut (%) 7.03 5.43 4.98 3.22 10.00 5.35 N.D
CD4/8 1.598 0.33 2.52 0.36 1.72 0.55 N.D
AEP, smoking-induced acute eosinophilic pneumonia; CEP, chronic idiopathic eosinophilic pneumonia; Drug-EP, drug-induced eosino-
philic pneumonia; IPF, idiopathic pulmonary fibrosis; Sar, sarcoidosis; HV, healthy volunteers.
Data are expressed as mean SEM.
36 O. Matsuno et al.The cause of the Drug-EP in four of eight cases was
confirmed by the provocation test, and withdrawal of the
causative drugs led to a favorable outcome without specific
treatment. The four cases were described in previous
papers.19,20
Determination of serum sADAM8 and sCD23 levels
Serum sADAM8 and sCD23 concentrations were measured
using a commercially available enzyme-linked immunosor-
bent assay (ELISA) kit according to the manufacturer’s
protocol. A Quantikine kit from R & D Systems (Minneapolis,
MN) was used to quantify sADAM8. A human sCD23 ELISA kit
(Bender MedSystems, Vienna, Austria) was used to quantify
CD23. The minimal detectable levels were 5.27 pg/ml
(sADAM8) and 6.8 U/ml (sCD23).
Statistical analysis
The KruskaleWallis test was used to compare values
between more than two groups. In case of a significant
difference between groups, differences between pairs of
group were analyzed by a ManneWhitney U test. CorrelationFigure 1 (a) Concentration of ADAM8 in serum obtained from pati
chronic idiopathic eosinophilic pneumonia (CEP), drug-induced p
differences are shown at the top. (b) Concentration of CD23 in s
Significant differences are shown at the top.coefficients were determined by Pearson’s linear regression
analysis between sADAM8 and sCD23. Correlation coeffi-
cients between longitudinal changes in ADAM8 concentra-
tions and the delay in obtaining BALF after the clinical onset
and provocation test were determined by Spearman’s
method. A difference was considered significant when the
p-value was less than 0.05.
Results
sADAM8 and sCD23 concentrations in the serum
from patients with various diffuse lung diseases
The serums ADAM8 and sCD23 concentrations were
measured by ELISA. sADAM8 concentrations were not
significantly elevated in non-eosinophilic conditions, such as
IPF (mean SEM; 294.6 52.16), sarcoidosis (295.6
26.43), or in HV (239.8 23.87). The sADAM8 concentrations
were significantly elevated in AEP (pZ 0.0395), CEP
(pZ 0.0001), and Drug-EP (pZ<0.0001), in comparison
with HV (Fig. 1a). There was significant difference in serum
ADAM8 concentrations between AEP and Drug-EP (pZ
0.0426) (Fig. 1a). The CD23 concentrations were significantlyents with smoking-induced acute eosinophilic pneumonia (AEP),
neumonia (Drug-EP), and healthy volunteers (HV). Significant
erum obtained from patients with AEP, CEP, Drug-EP, and HV.
Figure 3 Relationship between ADAM8 and CD23 concentra-
tions in serum from patients with Drug-EP.
Soluble ADAM8 in eosinophilic pneumonia 37elevated in CEP (pZ 0.0058) and Drug-EP (pZ 0.0018),
compared with HV (Fig. 1b). Serum CD23 concentrations did
not differ between the different types of EP.
Longitudinal changes in ADAM8 concentrations in
serum obtained after the clinical onset and
provocation test
The serum ADAM8 concentrations differed significantly
between the clinical onset and provocation test (Fig. 2).
Prednisone treatment could not be responsible for the
decline inADAM8,because all cases improved spontaneously.
Relationship between serum sADAM8 and sCD23
concentrations
There was significant correlation between the sADAM8 and
sCD23 concentrations in the serum from patients with Drug-
EP (pZ 0.0080, R2Z 0.8465; Fig. 3), but not AEP and CEP
(data not shown), although sADAM8 and sCD23 concentra-
tions were significantly elevated in CEP. These results
suggest that ADAM8 was the main sheddase for CD23 in
Drug-EP, but not AEP and CEP.
Discussion
ADAM8 is strongly associated with allergic airway inflam-
mation in humans and mice, and recent studies of ADAM8
are beginning to provide insight into its role in asthma and
eosinophilic pneumonia pathogenesis. The potential
importance of ADAM8 in eosinophil inflammation is also
highlighted by a reported microarray analysis of whole lung
from mice in which ADAM8 mRNA was upregulated after
antigen challenge with ovalbumin.13 Eosinophils are
a major source of ADAM8 mRNA. Gene-targeted mouse
studies revealed that ovalbumin-induced ADAM8 is largely
dependent on the signal transduction and activation of
STAT-6 and interleukin-4 a-chain.13 A recent study identi-
fied CD23, L-selectin,21 P-selectin glycoprotein ligand-1,21
and vascular cell adhesion molecule as specific substrates
for the metalloproteinase associated with ADAM8.6 We
previously reported that sADAM8 has a physiologic role inFigure 2 Longitudinal changes in ADAM8 concentration in
serum obtained after clinical onset and provocation test in
Drug-EP.protecting against allergic pulmonary disease in experi-
mental murine asthma.14 ADAM8 concentrations in BALF are
significantly elevated in AEP and CEP in comparison with
HV.15 These findings indicate that ADAM8 is associated with
allergic lung inflammation in humans.
ADAM8 converts membrane-bound CD23 into a soluble
form that might be involved in the regulation of IgE
synthesis and the activation of macrophages to release
a variety of pro-inflammatory mediators, although the role
of soluble CD23 in human allergic lung inflammation is not
yet clear. Mice deficient in CD23 produce higher levels of
IgE than their wild-type counterparts22 without any effect
on B cell or Tcell growth and differentiation.22e24
Conversely, mice overexpressing membrane CD23 exhibit
a weaker IgE response.24 In contrast, CD23 knockout mice do
not exhibit an antigen-specific IgE-mediated antibody
response.25 Membrane CD23 negatively regulates pulmonary
inflammation and acute bronchial hyperresponsiveness.8,9
sCD23 acts to upregulate or downregulate the level of IgE
produced by activated human B cells, possibly by interacting
with or without the CD21/CD19 complex, suggesting a regu-
latory role for sCD23 in the regulation of IgE levels.26,27
sCD23 binding to CD11b/CD18, CD11c/CD18, and alphaV
integrins on monocytes increases their production of pro-
inflammatory cytokines.10e12
We previously demonstrated that sADAM8 levels are
increased in BALF samples from patients with smoking-
induced AEP and CEP, but not in BALF samples from patients
with Drug-EP.15 In contrast to the BALF findings, serum
ADAM8 concentrations were significantly higher in Drug-EP
compared to AEP. These findings indicate that the regula-
tion of sADAM8 differs between AEP and Drug-EP. Drug-EP is
caused by bloodstream allergens, whereas AEP is caused by
cigarette smoking (inhalation exposure to chemicals or
antigens). The pathogens or allergens related to CEP are
unclear. These findings indicate that the induction of
ADAM8 expression reflects the route of entry for chemicals
or antigens, although it is not clear why certain compounds
induce Th2-dominant immune responses. Changes in
sADAM8 concentrations were observed longitudinally in
serum obtained at clinical onset, during the resolution
phase (before the provocation test), and after the provo-
cation test. These results demonstrate that ADAM8 induc-
tion parallels drug-induced eosinophilic lung inflammation.
38 O. Matsuno et al.The findings of the present study are the first to demon-
strate changes in serum sADAM8 levels after allergen chal-
lenge. Drug-EP often has an acute onset and is difficult to
distinguish from AEP. Together with these clinical findings,
evaluation of ADAM8 in BALF and serum may contribute to
distinguishing between Drug-EP from AEP.
We previously demonstrated that sCD23 concentrations
are significantly elevated in BALF only in patients with AEP.
In addition, the sADAM8 and sCD23 concentrations are
significantly correlated in BALF from patients with AEP, but
not CEP and Drug-EP.15 In contrast, in the present study,
serum sCD23 concentrations were not elevated in AEP. The
serum sCD23 concentrations were significantly elevated in
patients with Drug-EP compared with HV. Serum ADAM8 and
CD23 concentrations correlated significantly in patients
with Drug-EP, but not in those with AEP or CEP. These
findings suggest that ADAM8 regulates the degradation of
CD23 in the serum in Drug-EP; on the other hand, a protease
other than ADAM8, such as ADAM10 or other proteases28
might regulate the degradation of CD23 in AEP and CEP.
The difference in the ADAM8 concentrations between
AEP, CEP, and Drug-EP, as well as the relation of ADAM8 to
CD23 concentrations indicates that the pathogenesis of
AEP, CEP, and Drug-EP is distinct, although the accumula-
tion of eosinophils in the lungs is a common feature. The
pathogenesis of AEP and Drug-EP may be distinct with
regard to allergen exposure; AEP is caused by inhalation of
chemicals or allergens, whereas Drug-EP is caused by
bloodstream antigens. ADAM8 levels reflect the pathogen-
esis of eosinophilic inflammation in Drug-EP.
This study is the first finding to demonstrate that the
antigen exposure route, i.e., inhalation versus and blood-
stream exposure, differentially activates inflammatory and
structural cells in the lung in association with ADAM8
expression in serum and BALF. This study provides further
insight into eosinophilic inflammation and opens new
avenues for the recognition of allergic pulmonary disease.
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